A study of plasma disposition kinetics of lacidipine after single oral ascending doses.
This study was designed to assess the plasma disposition kinetics of single oral 4-, 6-, and 8-mg doses of lacidipine, a new once-daily calcium-entry blocker. Seventeen healthy volunteers attended the study. In almost all cases, detectable levels were found up to 24 h after the drug administration, using a new HPLC-RIA assay. The usual pharmacokinetic parameters were calculated: Cmax, tmax, AUCinf, lambda z and t1/2. The half-life was similar after all doses, around 7 h, whereas Cmax and AUCinf did not show a linear correlation with the doses.
Squassante
L
L
Glaxo S.p.A., Direzione Ricerche e Sviluppo, Verona, Italy.
Caveggion
E
E
Braggio
S
S
Pellegatti
M
M
Baroldi
P
P
D000284:Administration, Oral; D000328:Adult; D002121:Calcium Channel Blockers / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000494:pharmacology; D002851:Chromatography, High Pressure Liquid; D004095:Dihydropyridines / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000494:pharmacology; D005260:Female; D006207:Half-Life; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D008297:Male; D011863:Radioimmunoassay
D002121:Calcium Channel Blockers; D004095:Dihydropyridines; C060285:lacidipine